{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:05:21Z","timestamp":1792638321458,"version":"4.5.0"},"reference-count":126,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>High mobility group box 1 (HMGB1) protein is a damage-associated molecular\npattern (DAMP) that plays an important role in the repair and regeneration of tissue injury. It\nalso acts as a pro-inflammatory cytokine through the activation of toll-like receptor 4 (TLR4) and\nreceptor for advanced glycation end products (RAGE), to elicit the neuroinflammatory response.\nHMGB1 may aggravate several cellular responses, which may lead to pathological inflammation\nand cellular death. Thus, there have been a considerable amount of research into the pathological\nrole of HMGB1 in diseases. However, whether the mechanism of action of HMGB1 is similar in all\nneurodegenerative disease pathology remains to be determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Therefore, this systematic review aimed to critically evaluate and elucidate the role of\nHMGB1 in the pathology of neurodegeneration based on the available literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was performed on four databases; EMBASE, PubMed,\nScopus, and CINAHL Plus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 85 articles were selected for critical appraisal, after subjecting to the inclusion\nand exclusion criteria in this study. The selected articles revealed that HMGB1 levels were found\nelevated in most neurodegeneration except in Huntington\u2019s disease and Spinocerebellar ataxia,\nwhere the levels were found decreased. This review also showcased that HMGB1 may act on distinctive\npathways to elicit its pathological response leading to the various neurodegeneration processes\/\ndiseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>While there have been promising findings in HMGB1 intervention research, further\nstudies may still be required before any HMGB1 intervention may be recommended as a therapeutic\ntarget for neurodegenerative diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x20666220114153308","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:13:05Z","timestamp":1642378385000},"page":"2221-2245","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Role of High Mobility Group Box 1 (HMGB1) in Neurodegeneration:\nA Systematic Review"],"prefix":"10.2174","volume":"20","author":[{"given":"Mohd. Farooq","family":"Shaikh","sequence":"first","affiliation":[{"name":"Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fathimath Zaha","family":"Ikram","sequence":"additional","affiliation":[{"name":"Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Arulsamy","sequence":"additional","affiliation":[{"name":"Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaarvena","family":"Retinasamy","sequence":"additional","affiliation":[{"name":"Neuropharmacology Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.it.2005.04.009","volume":"26","author":"Dumitriu I.E.","year":"2005","unstructured":"Dumitriu I.E.; Baruah P.; Manfredi A.A.; Bianchi M.E.; Rovere-Querini P.; HMGB1: guiding immunity from within. Trends Immunol 2005,26(7),381-387","journal-title":"Trends Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"E383","DOI":"10.3390\/cells9020383","volume":"9","author":"Paudel Y.N.","year":"2020","unstructured":"Paudel Y.N.; Angelopoulou E.; Piperi C.; Othman I.; Aamir K.; Shaikh M.F.; Impact of HMGB1, RAGE, and TLR4 in Alzheimer\u2019s disease (AD): from risk factors to therapeutic targeting. Cells 2020,9(2),E383","journal-title":"Cells"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.gde.2005.08.007","volume":"15","author":"Bianchi M.E.","year":"2005","unstructured":"Bianchi M.E.; Agresti A.; HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005,15(5),496-506","journal-title":"Curr Opin Genet Dev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","volume":"6","author":"V&#xE9;n&#xE9;reau E.","year":"2015","unstructured":"V&#xE9;n&#xE9;reau E.; Ceriotti C.; Bianchi M.E.; DAMPs from cell death to new life. Front Immunol 2015,6,422","journal-title":"Front Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"104792","DOI":"10.1016\/j.phrs.2020.104792","volume":"156","author":"Paudel Y.N.","year":"2020","unstructured":"Paudel Y.N.; Angelopoulou E.; Piperi C.; Othman I.; Shaikh M.F.; Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results. Pharmacol Res 2020,156,104792","journal-title":"Pharmacol Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"172487","DOI":"10.1016\/j.ejphar.2019.172487","volume":"858","author":"Paudel Y.N.","year":"2019","unstructured":"Paudel Y.N.; Angelopoulou E.; Piperi C.; Balasubramaniam V.R.M.T.; Othman I.; Shaikh M.F.; Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling. Eur J Pharmacol 2019,858,172487","journal-title":"Eur J Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1021\/acs.jmedchem.7b01136","volume":"61","author":"VanPatten S.","year":"2018","unstructured":"VanPatten S.; Al-Abed Y.; High Mobility Group Box-1 (HMGb1): current wisdom and advancement as a potential drug target. J Med Chem 2018,61(12),5093-5107","journal-title":"J Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fncel.2018.00072","volume":"12","author":"Skaper S.D.","year":"2018","unstructured":"Skaper S.D.; Facci L.; Zusso M.; Giusti P.; An inflammation-centric view of neurological disease: beyond the neuron. Front Cell Neurosci 2018,12,72","journal-title":"Front Cell Neurosci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","volume":"25","author":"Furman D.","year":"2019","unstructured":"Furman D.; Campisi J.; Verdin E.; Carrera-Bastos P.; Targ S.; Franceschi C.; Ferrucci L.; Gilroy D.W.; Fasano A.; Miller G.W.; Mil-ler A.H.; Mantovani A.; Weyand C.M.; Barzilai N.; Goronzy J.J.; Rando T.A.; Effros R.B.; Lucia A.; Kleinstreuer N.; Slavich G.M.; Chronic inflammation in the etiology of disease across the life span. Nat Med 2019,25(12),1822-1832","journal-title":"Nat Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","volume":"29","author":"Gao H-M.","year":"2008","unstructured":"Gao H-M.; Hong J-S.; Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008,29(8),357-365","journal-title":"Trends Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"Dugger B.N.","year":"2017","unstructured":"Dugger B.N.; Dickson D.W.; Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017,9(7),a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"Przedborski S.","year":"2003","unstructured":"Przedborski S.; Vila M.; Jackson-Lewis V.; Neurodegeneration: what is it and where are we? J Clin Invest 2003,111(1),3-10","journal-title":"J Clin Invest"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Hou Y.","year":"2019","unstructured":"Hou Y.; Dan X.; Babbar M.; Wei Y.; Hasselbalch S.G.; Croteau D.L.; Bohr V.A.; Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 2019,15(10),565-581","journal-title":"Nat Rev Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","volume":"35","author":"Wyss-Coray T.","year":"2002","unstructured":"Wyss-Coray T.; Mucke L.; Inflammation in neurodegenerative disease--a double-edged sword. Neuron 2002,35(3),419-432","journal-title":"Neuron"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1038\/cddis.2011.50","volume":"2","author":"Garwood C.J.","year":"2011","unstructured":"Garwood C.J.; Pooler A.M.; Atherton J.; Hanger D.P.; Noble W.; Astrocytes are important mediators of A&#x3B2;-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2011,2(6),e167","journal-title":"Cell Death Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1196\/annals.1332.006","volume":"1035","author":"Kitazawa M.","year":"2004","unstructured":"Kitazawa M.; Yamasaki T.R.; LaFerla F.M.; Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci 2004,1035,85-103","journal-title":"Ann N Y Acad Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12035-012-8267-8","volume":"47","author":"Lema Tom&#xE9; C.M.","year":"2013","unstructured":"Lema Tom&#xE9; C.M.; Tyson T.; Rey N.L.; Grathwohl S.; Britschgi M.; Brundin P.; Inflammation and &#x3B1;-synuclein\u2019s prion-like behavior in Parkinson\u2019s disease--is there a link? Mol Neurobiol 2013,47(2),561-574","journal-title":"Mol Neurobiol"},{"key":"ref=18","first-page":"1003","volume":"1","author":"Kempuraj D.","year":"2016","unstructured":"Kempuraj D.; Thangavel R.; Natteru P.A.; Selvakumar G.P.; Saeed D.; Zahoor H.; Zaheer S.; Iyer S.S.; Zaheer A.; Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 2016,1(1),1003","journal-title":"J Neurol Neurosurg Spine"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"Moher D.","year":"2015","unstructured":"Moher D.; Shamseer L.; Clarke M.; Ghersi D.; Liberati A.; Petticrew M.; Shekelle P.; Stewart L.A.; Preferred reporting items for sys-tematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015,4(1),1","journal-title":"Syst Rev"},{"key":"ref=20","author":"Project EPHP","year":"1998","unstructured":"Project EPHP;  Quality assessment tool for quantitative studies 1998","journal-title":"Quality assessment tool for quantitative studies"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"Hooijmans C.R.","year":"2014","unstructured":"Hooijmans C.R.; Rovers M.M.; de Vries R.B.M.; Leenaars M.; Ritskes-Hoitinga M.; Langendam M.W.; SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 2014,14(1),43","journal-title":"BMC Med Res Methodol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12974-016-0670-z","volume":"13","author":"Festoff B.W.","year":"2016","unstructured":"Festoff B.W.; Sajja R.K.; van Dreden P.; Cucullo L.; HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as bi-omarkers of neuroinflammation and progression to neurodegeneration in Alzheimer\u2019s disease. J Neuroinflammation 2016,13(1),194","journal-title":"J Neuroinflammation"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jprot.2016.03.022","volume":"139","author":"Minjarez B.","year":"2016","unstructured":"Minjarez B.; Calder&#xF3;n-Gonz&#xE1;lez K.G.; Rustarazo M.L.V.; Herrera-Aguirre M.E.; Labra-Barrios M.L.; Rincon-Limas D.E.; Del Pino M.M.; Mena R.; Luna-Arias J.P.; Identification of proteins that are differentially expressed in brains with Alzheimer\u2019s disease using iTRAQ labeling and tandem mass spectrometry. J Proteomics 2016,139,103-121","journal-title":"J Proteomics"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"685739","DOI":"10.1155\/2012\/685739","volume":"2012","author":"Takata K.","year":"2012","unstructured":"Takata K.; Takada T.; Ito A.; Asai M.; Tawa M.; Saito Y.; Ashihara E.; Tomimoto H.; Kitamura Y.; Shimohama S.; Microglial Amy-loid-&#x3B2;1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer\u2019s Disease. Int J Alzheimers Dis 2012,2012,685739","journal-title":"Int J Alzheimers Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0006-291X(03)00024-X","volume":"301","author":"Takata K.","year":"2003","unstructured":"Takata K.; Kitamura Y.; Kakimura J.; Shibagaki K.; Tsuchiya D.; Taniguchi T.; Smith M.A.; Perry G.; Shimohama S.; Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 2003,301(3),699-703","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3233\/JAD-160912","volume":"55","author":"Nilson A.N.","year":"2017","unstructured":"Nilson A.N.; English K.C.; Gerson J.E.; Barton Whittle T.; Nicolas Crain C.; Xue J.; Sengupta U.; Castillo-Carranza D.L.; Zhang W.; Gupta P.; Kayed R.; Tau oligomers associate with inflammation in the brain and retina of tauopathy mice and in neurodegenerative dis-eases. J Alzheimers Dis 2017,55(3),1083-1099","journal-title":"J Alzheimers Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"31895","DOI":"10.1038\/srep31895","volume":"6","author":"Fujita K.","year":"2016","unstructured":"Fujita K.; Motoki K.; Tagawa K.; Chen X.; Hama H.; Nakajima K.; Homma H.; Tamura T.; Watanabe H.; Katsuno M.; Matsumi C.; Kajikawa M.; Saito T.; Saido T.; Sobue G.; Miyawaki A.; Okazawa H.; HMGB1, a pathogenic molecule that induces neurite degenera-tion via TLR4-MARCKS, is a potential therapeutic target for Alzheimer\u2019s disease. Sci Rep 2016,6(1),31895","journal-title":"Sci Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12031-017-0989-7","volume":"63","author":"Kong Z.H.","year":"2017","unstructured":"Kong Z.H.; Chen X.; Hua H.P.; Liang L.; Liu L.J.; The oral pretreatment of glycyrrhizin prevents surgery-induced cognitive impairment in aged mice by reducing neuroinflammation and Alzheimer\u2019s-related pathology via HMGB1 inhibition. J Mol Neurosci 2017,63(3-4),385-395","journal-title":"J Mol Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41419-020-03293-0","volume":"11","author":"Lee Y-S.","year":"2020","unstructured":"Lee Y-S.; Choi J-Y.; Mankhong S.; Moon S.; Kim S.; Koh Y.H.; Kim J.H.; Kang J.H.; Sirtuin 1-dependent regulation of high mobility box 1 in hypoxia-reoxygenated brain microvascular endothelial cells: roles in neuronal amyloidogenesis. Cell Death Dis 2020,11(12),1072","journal-title":"Cell Death Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1523\/JNEUROSCI.2052-12.2013","volume":"33","author":"Meneghini V.","year":"2013","unstructured":"Meneghini V.; Bortolotto V.; Francese M.T.; Dellarole A.; Carraro L.; Terzieva S.; Grilli M.; High-mobility group box-1 protein and &#x3B2;-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products\/nuclear factor-&#x3BA;B axis: relevance for Alzheimer\u2019s disease. J Neurosci 2013,33(14),6047-6059","journal-title":"J Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.intimp.2018.12.027","volume":"67","author":"Nan K.","year":"2019","unstructured":"Nan K.; Han Y.; Fang Q.; Huang C.; Yu L.; Ge W.; Xiang F.; Tao Y.X.; Cao H.; Li J.; HMGB1 gene silencing inhibits neuroinflamma-tion via down-regulation of NF-&#x3BA;B signaling in primary hippocampal neurons induced by A&#x3B2;25-35. Int Immunopharmacol 2019,67,294-301","journal-title":"Int Immunopharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbrc.2017.11.035","volume":"495","author":"Oh S.","year":"2018","unstructured":"Oh S.; Son M.; Choi J.; Lee S.; Byun K.; sRAGE prolonged stem cell survival and suppressed RAGE-related inflammatory cell and T lymphocyte accumulations in an Alzheimer\u2019s disease model. Biochem Biophys Res Commun 2018,495(1),807-813","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/jnr.20340","volume":"78","author":"Takata K.","year":"2004","unstructured":"Takata K.; Kitamura Y.; Tsuchiya D.; Kawasaki T.; Taniguchi T.; Shimohama S.; High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res 2004,78(6),880-891","journal-title":"J Neurosci Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3233\/JAD-191110","volume":"74","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; Hua X.F.; Gu J.; Chen F.; Gu J.; Gong C.X.; Liu F.; Dai C.L.; High mobility group box 1 ameliorates cognitive impairment in the 3&#xD7;Tg-AD mouse model. J Alzheimers Dis 2020,74(3),851-864","journal-title":"J Alzheimers Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/15384101.2020.1863681","volume":"20","author":"Zhang Y.Y.","year":"2021","unstructured":"Zhang Y.Y.; Bao H.L.; Dong L.X.; Liu Y.; Zhang G.W.; An F.M.; Silenced lncRNA H19 and up-regulated microRNA-129 accelerates viability and restrains apoptosis of PC12 cells induced by A&#x3B2;25-35 in a cellular model of Alzheimer\u2019s disease. Cell Cycle 2021,20(1),112-125","journal-title":"Cell Cycle"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"110131","DOI":"10.1016\/j.biopha.2020.110131","volume":"127","author":"Zhang Z.","year":"2020","unstructured":"Zhang Z.; Liu H.; Zhao Z.; Zang C.; Ju C.; Li F.; Wang L.; Yang H.; Bao X.; Yu Y.; Yao X.; Zhang D.; GJ-4 alleviates A&#x3B2;25-35-induced memory dysfunction in mice through protecting the neurovascular unit. Biomed Pharmacother 2020,127,110131","journal-title":"Biomed Pharmacother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"172857","DOI":"10.1016\/j.ejphar.2019.172857","volume":"869","author":"Zhou Z.","year":"2020","unstructured":"Zhou Z.; Hou J.; Mo Y.; Ren M.; Yang G.; Qu Z.; Hu Y.; Geniposidic acid ameliorates spatial learning and memory deficits and allevi-ates neuroinflammation via inhibiting HMGB-1 and downregulating TLR4\/2 signaling pathway in APP\/PS1 mice. Eur J Pharmacol 2020,869,172857","journal-title":"Eur J Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2174\/15672050113109990135","volume":"10","author":"Jang A.","year":"2013","unstructured":"Jang A.; Liew H.; Kim Y.M.; Choi H.; Kim S.; Lee S.H.; Ohshima T.; Mikoshiba K.; Suh Y.H.; p35 deficiency accelerates HMGB-1-mediated neuronal death in the early stages of an Alzheimer\u2019s disease mouse model. Curr Alzheimer Res 2013,10(8),829-843","journal-title":"Curr Alzheimer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e00948","DOI":"10.1002\/brb3.948","volume":"8","author":"Yang Y.","year":"2018","unstructured":"Yang Y.; Han C.; Guo L.; Guan Q.; High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson\u2019s disease and the relationship of pathological staging. Brain Behav 2018,8(4),e00948","journal-title":"Brain Behav"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nbd.2016.02.018","volume":"91","author":"Santoro M.","year":"2016","unstructured":"Santoro M.; Maetzler W.; Stathakos P.; Martin H.L.; Hobert M.A.; Rattay T.W.; Gasser T.; Forrester J.V.; Berg D.; Tracey K.J.; Riedel G.; Teismann P.; In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson\u2019s disease which can be attenuated by glycyrrhizin. Neurobiol Dis 2016,91,59-68","journal-title":"Neurobiol Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fphar.2020.00776","volume":"11","author":"Gan P.","year":"2020","unstructured":"Gan P.; Ding L.; Hang G.; Xia Q.; Huang Z.; Ye X.; Qian X.; Oxymatrine attenuates dopaminergic neuronal damage and microglia-mediated neuroinflammation through cathepsin D-dependent HMGB1\/TLR4\/NF-&#x3BA;B pathway in Parkinson\u2019s disease. Front Pharmacol 2020,11,776","journal-title":"Front Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1523\/JNEUROSCI.3732-10.2011","volume":"31","author":"Gao H-M.","year":"2011","unstructured":"Gao H-M.; Zhou H.; Zhang F.; Wilson B.C.; Kam W.; Hong J-S.; HMGB1 acts on microglia Mac1 to mediate chronic neuroinflamma-tion that drives progressive neurodegeneration. J Neurosci 2011,31(3),1081-1092","journal-title":"J Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fnmol.2017.00013","volume":"10","author":"Huang J.","year":"2017","unstructured":"Huang J.; Yang J.; Shen Y.; Jiang H.; Han C.; Zhang G.; Liu L.; Xu X.; Li J.; Lin Z.; Xiong N.; Zhang Z.; Xiong J.; Wang T.; HMGB1 mediates autophagy dysfunction via perturbing Beclin1-Vps34 complex in dopaminergic cell model. Front Mol Neurosci 2017,10(13),13","journal-title":"Front Mol Neurosci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s12640-019-00148-1","volume":"37","author":"Huang M.","year":"2020","unstructured":"Huang M.; Guo M.; Wang K.; Wu K.; Li Y.; Tian T.; Wang Y.; Yan W.; Zhou Z.; Yang H.; HMGB1 mediates paraquat-induced neu-roinflammatory responses via activating RAGE signaling pathway. Neurotox Res 2020,37(4),913-925","journal-title":"Neurotox Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41374-019-0254-5","volume":"99","author":"Kim S.J.","year":"2019","unstructured":"Kim S.J.; Ryu M.J.; Han J.; Jang Y.; Lee M.J.; Ju X.; Ryu I.; Lee Y.L.; Oh E.; Chung W.; Heo J.Y.; Kweon G.R.; Non-cell autonomous modulation of tyrosine hydroxylase by HMGB1 released from astrocytes in an acute MPTP-induced Parkinsonian mouse model. Lab Invest 2019,99(9),1389-1399","journal-title":"Lab Invest"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.lfs.2019.03.030","volume":"223","author":"Lv R.","year":"2019","unstructured":"Lv R.; Du L.; Liu X.; Zhou F.; Zhang Z.; Zhang L.; Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1\/TLR4\/NF-&#x3BA;B signaling pathway in a mouse model of Parkinson\u2019s disease. Life Sci 2019,223,158-165","journal-title":"Life Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.expneurol.2015.11.003","volume":"275","author":"Sasaki T.","year":"2016","unstructured":"Sasaki T.; Liu K.; Agari T.; Yasuhara T.; Morimoto J.; Okazaki M.; Takeuchi H.; Toyoshima A.; Sasada S.; Shinko A.; Kondo A.; Kameda M.; Miyazaki I.; Asanuma M.; Borlongan C.V.; Nishibori M.; Date I.; Anti-high mobility group box 1 antibody exerts neuro-protection in a rat model of Parkinson\u2019s disease. Exp Neurol 2016,275(Pt 1),220-231","journal-title":"Exp Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2018.03.031","volume":"202","author":"Guan Y.","year":"2018","unstructured":"Guan Y.; Li Y.; Zhao G.; Li Y.; HMGB1 promotes the starvation-induced autophagic degradation of &#x3B1;-synuclein in SH-SY5Y cells Atg 5-dependently. Life Sci 2018,202,1-10","journal-title":"Life Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1042\/CS20200553","volume":"134","author":"Tian Y.","year":"2020","unstructured":"Tian Y.; Cao Y.; Chen R.; Jing Y.; Xia L.; Zhang S.; HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson\u2019s disease model. Clin Sci (Lond) 2020,134(15),2075-2090","journal-title":"Clin Sci (Lond)"},{"key":"ref=50","first-page":"2735","volume":"15","author":"Lindersson E.K.","year":"2004","unstructured":"Lindersson E.K.; H&#xF8;jrup, P.; Gai, W.P.; Locker, D.; Martin, D.; Jensen, P.H. &#x3B1;-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport 2004,15(18),2735-2739","journal-title":"Neuroreport"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e1000749","DOI":"10.1371\/journal.pgen.1000749","volume":"5","author":"Goula A.V.","year":"2009","unstructured":"Goula A.V.; Berquist B.R.; Wilson D.M.; Wheeler V.C.; Trottier Y.; Merienne K.; Stoichiometry of base excision repair proteins correlates with increased somatic CAG instability in striatum over cerebellum in Huntington\u2019s disease transgenic mice. PLoS Genet 2009,5(12),e1000749","journal-title":"PLoS Genet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12688\/f1000research.6358.1","volume":"4","author":"Kalathur R.K.","year":"2015","unstructured":"Kalathur R.K.; Giner-Lamia J.; Machado S.; Barata T.; Ayasolla K.R.; Futschik M.E.; The unfolded protein response and its potential role in Huntington\u2019s disease elucidated by a systems biology approach. F1000 Res 2015,4,103","journal-title":"F1000 Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1074\/jbc.RA117.001440","volume":"294","author":"Son S.","year":"2019","unstructured":"Son S.; Bowie L.E.; Maiuri T.; Hung C.L.K.; Desmond C.R.; Xia J.; Truant R.; High-mobility group box 1 links sensing of reactive oxygen species by huntingtin to its nuclear entry. J Biol Chem 2019,294(6),1915-1923","journal-title":"J Biol Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.4049\/jimmunol.1202472","volume":"190","author":"Min H.J.","year":"2013","unstructured":"Min H.J.; Ko E.A.; Wu J.; Kim E.S.; Kwon M.K.; Kwak M.S.; Choi J.E.; Lee J.E.; Shin J.S.; Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. J Immunol 2013,190(4),1797-1806","journal-title":"J Immunol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/ncb1553","volume":"9","author":"Qi M.L.","year":"2007","unstructured":"Qi M.L.; Tagawa K.; Enokido Y.; Yoshimura N.; Wada Y.; Watase K.; Ishiura S.; Kanazawa I.; Botas J.; Saitoe M.; Wanker E.E.; Okazawa H.; Proteome analysis of soluble nuclear proteins reveals that HMGB1\/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 2007,9(4),402-414","journal-title":"Nat Cell Biol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2013.04.013","volume":"58","author":"Hwang C.S.","year":"2013","unstructured":"Hwang C.S.; Liu G.T.; Chang M.D.; Liao I.L.; Chang H.T.; Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis. Neurobiol Dis 2013,58,13-18","journal-title":"Neurobiol Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3389\/fncel.2015.00485","volume":"9","author":"Juranek J.K.","year":"2015","unstructured":"Juranek J.K.; Daffu G.K.; Wojtkiewicz J.; Lacomis D.; Kofler J.; Schmidt A.M.; Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front Cell Neurosci 2015,9,485","journal-title":"Front Cell Neurosci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuroscience.2011.02.001","volume":"179","author":"Casula M.","year":"2011","unstructured":"Casula M.; Iyer A.M.; Spliet W.G.; Anink J.J.; Steentjes K.; Sta M.; Troost D.; Aronica E.; Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011,179,233-243","journal-title":"Neuroscience"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12974-019-1435-2","volume":"16","author":"Lee J.D.","year":"2019","unstructured":"Lee J.D.; Liu N.; Levin S.C.; Ottosson L.; Andersson U.; Harris H.E.; Woodruff T.M.; Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2019,16(1),45","journal-title":"J Neuroinflammation"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neulet.2006.10.063","volume":"412","author":"Lo Coco D.","year":"2007","unstructured":"Lo Coco D.; Veglianese P.; Allievi E.; Bendotti C.; Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci Lett 2007,412(1),73-77","journal-title":"Neurosci Lett"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neuroscience.2018.05.042","volume":"384","author":"Meyer M.","year":"2018","unstructured":"Meyer M.; Lara A.; Hunt H.; Belanoff J.; de Kloet E.R.; Gonzalez Deniselle M.C.; De Nicola A.F.; The selective glucocorticoid receptor modulator cort 113176 reduces neurodegeneration and neuroinflammation in wobbler mice spinal cord. Neuroscience 2018,384,384-396","journal-title":"Neuroscience"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fnins.2018.00622","volume":"12","author":"Brambilla L.","year":"2018","unstructured":"Brambilla L.; Martorana F.; Guidotti G.; Rossi D.; Dysregulation of astrocytic HMGB1 signaling in amyotrophic lateral sclerosis. Front Neurosci 2018,12,622","journal-title":"Front Neurosci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s12035-018-1220-8","volume":"56","author":"Gomes C.","year":"2019","unstructured":"Gomes C.; Cunha C.; Nascimento F.; Ribeiro J.A.; Vaz A.R.; Brites D.; Cortical neurotoxic astrocytes with early ALS pathology and miR-146a deficit replicate gliosis markers of symptomatic SOD1G93A mouse model. Mol Neurobiol 2019,56(3),2137-2158","journal-title":"Mol Neurobiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1007\/s12035-020-02019-9","volume":"57","author":"Lee J.D.","year":"2020","unstructured":"Lee J.D.; McDonald T.S.; Fung J.N.T.; Woodruff T.M.; Absence of receptor for advanced glycation end product (RAGE) reduces in-flammation and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Mol Neurobiol 2020,57(10),4143-4155","journal-title":"Mol Neurobiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12974-015-0310-z","volume":"12","author":"Lee J.Y.","year":"2015","unstructured":"Lee J.Y.; Lee J.D.; Phipps S.; Noakes P.G.; Woodruff T.M.; Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 2015,12,90","journal-title":"J Neuroinflammation"},{"key":"ref=66","first-page":"4207","volume":"55","author":"Cunha C.","year":"2018","unstructured":"Cunha C.; Santos C.; Gomes C.; Fernandes A.; Correia A.M.; Sebasti&#xE3;o A.M.; Vaz A.R.; Brites D.; Downregulated glia interplay and increased miRNA-155 as promising markers to track ALS at an early stage. Mol Neurobiol 2018,55(5),4207-4224","journal-title":"Mol Neurobiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1189\/jlb.1207844","volume":"84","author":"Andersson A.","year":"2008","unstructured":"Andersson A.; Covacu R.; Sunnemark D.; Danilov A.I.; Dal Bianco A.; Khademi M.; Wallstr&#xF6;m E.; Lobell A.; Brundin L.; Lass-mann H.; Harris R.A.; Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008,84(5),1248-1255","journal-title":"J Leukoc Biol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"198","DOI":"10.29252\/rbmb.9.2.199","volume":"9","author":"Asouri M.","year":"2020","unstructured":"Asouri M.; Alinejad Rokni H.; Sahraian M.A.; Fattahi S.; Motamed N.; Doosti R.; Rahimi H.; Lotfi M.; Moslemi A.; Karimpoor M.; Mahboudi F.; Akhavan-Niaki H.; Analysis of single nucleotide polymorphisms in HLA-DRA, IL2RA, and HMGB1 genes in multiple scle-rosis. Rep Biochem Mol Biol 2020,9(2),198-208","journal-title":"Rep Biochem Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10072-019-04136-3","volume":"41","author":"Bucova M.","year":"2020","unstructured":"Bucova M.; Majernikova B.; Durmanova V.; Cudrakova D.; Gmitterova K.; Lisa I.; Klimova E.; Kluckova K.; Buc M.; HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol Sci 2020,41(3),599-604","journal-title":"Neurol Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3389\/fimmu.2018.01240","volume":"9","author":"D\u2019Angelo C.","unstructured":"D\u2019Angelo C.; Reale M.; Costantini E.; Di Nicola M.; Porfilio I.; de Andr&#xE9;s C.; Fern&#xE1;ndez-Paredes L.; S&#xE1;nchez-Ram&#xF3;n S.; Pasquali L.;  ,9(JUN),1240"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000357002","volume":"21","year":"2014","unstructured":"Glasnovi\u0107 A.; Cvija, H.; Stoji\u0107 M.; Tudori\u0107-\u0110eno, I.; Iv&#x10D;evi\u0107 S.; Romi\u0107 D.; Ti&#x10D;inovi\u0107 N.; Vuleti\u0107 V.; Lazibat, I.; Gr&#x10D;evi\u0107 D. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset. Neuroimmunomodulation 2014,21(5),226-233","journal-title":"Neuroimmunomodulation"},{"key":"ref=72","first-page":"75","volume":"15","author":"Hamid K.M.","year":"2016","unstructured":"Hamid K.M.; Nejati A.; Shoja Z.; Mollaei-Kandelousd Y.; Doosti R.; Mirshafiey A.; Tafakhori A.; Sahraian M.A.; Marashi S.M.; Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis. Iran J Allergy Asthma Immunol 2016,15(1),75-81","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-015-0269-9","volume":"12","author":"Malhotra S.","year":"2015","unstructured":"Malhotra S.; Fissolo N.; Tintor&#xE9; M.; Wing A.C.; Castill&#xF3; J.; Vidal-Jordana A.; Montalban X.; Comabella M.; Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. J Neuroinflammation 2015,12,48","journal-title":"J Neuroinflammation"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"577107","DOI":"10.1016\/j.jneuroim.2019.577107","volume":"338","author":"Nasi M.","year":"2020","unstructured":"Nasi M.; Bianchini E.; De Biasi S.; Gibellini L.; Neroni A.; Mattioli M.; Pinti M.; Iannone A.; Mattioli A.V.; Simone A.M.; Ferraro D.; Vitetta F.; Sola P.; Cossarizza A.; Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. J Neuroimmunol 2020,338,577107","journal-title":"J Neuroimmunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12026-015-8673-x","volume":"64","author":"Sternberg Z.","year":"2016","unstructured":"Sternberg Z.; Sternberg D.; Chichelli T.; Drake A.; Patel N.; Kolb C.; Chadha K.; Yu J.; Hojnacki D.; High-mobility group box 1 in multiple sclerosis. Immunol Res 2016,64(2),385-391","journal-title":"Immunol Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.neuropharm.2017.11.047","volume":"130","author":"Sternberg Z.","year":"2018","unstructured":"Sternberg Z.; Kolb C.; Chadha K.; Nir A.; Nir R.; George R.; Johnson J.; Yu J.; Hojnacki D.; Fingolimod anti-inflammatory and neu-roprotective effects modulation of RAGE axis in multiple sclerosis patients. Neuropharmacology 2018,130,71-76","journal-title":"Neuropharmacology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000345994","volume":"20","author":"Wang H.","year":"2013","unstructured":"Wang H.; Wang K.; Wang C.; Xu F.; Zhong X.; Qiu W.; Hu X.; Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 2013,20(2),113-118","journal-title":"Neuroimmunomodulation"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.neuroscience.2012.08.041","volume":"226","author":"Wang K.C.","year":"2012","unstructured":"Wang K.C.; Tsai C.P.; Lee C.L.; Chen S.Y.; Chin L.T.; Chen S.J.; Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 2012,226,510-516","journal-title":"Neuroscience"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4149\/BLL_2019_120","volume":"120","author":"Bucova M.","year":"2019","unstructured":"Bucova M.; Durmanova V.; Cudrakova D.; Blazickova S.; Gmitterova K.; Klimova E.; Lisa I.; Kluckova K.; Majernikova B.; De-creased plasma levels of 25(OH)D in multiple sclerosis patients. Correlation with disease severity expressed by EDSS, MSSS, progression index and Herbert\u2019s scale severity grade. Bratisl Lek Listy 2019,120(10),723-729","journal-title":"Bratisl Lek Listy"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/jnnp-2012-304039","volume":"84","author":"Uzawa A.","year":"2013","unstructured":"Uzawa A.; Mori M.; Masuda S.; Muto M.; Kuwabara S.; CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2013,84(5),517-522","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"9030","DOI":"10.1073\/pnas.1818348116","volume":"116","author":"Nicaise A.M.","year":"2019","unstructured":"Nicaise A.M.; Wagstaff L.J.; Willis C.M.; Paisie C.; Chandok H.; Robson P.; Fossati V.; Williams A.; Crocker S.J.; Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Natl Acad Sci USA 2019,116(18),9030-9039","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"577480","DOI":"10.1016\/j.jneuroim.2021.577480","volume":"352","author":"Chu Y.","year":"2021","unstructured":"Chu Y.; Jing Y.; Zhao X.; Wang M.; Zhang M.; Ma R.; Ma W.; Lv Y.; Zhu L.; Modulation of the HMGB1\/TLR4\/NF-&#x3BA;B signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis. J Neuroimmunol 2021,352,577480","journal-title":"J Neuroimmunol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biopha.2017.09.110","volume":"96","year":"2017","unstructured":"Djedovi\u0107 N.; Stanisavljevic, S.; Jevti\u0107 B.; Mom&#x10D;ilovi\u0107 M.; Lavrnja, I.; Miljkovi\u0107 D. Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut. Biomed Pharmacother 2017,96,78-85","journal-title":"Biomed Pharmacother"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1039\/C5RA18974H","volume":"6","author":"Latha T.S.","year":"2016","unstructured":"Latha T.S.; Lomada D.; Dharani P.K.; Muthukonda S.V.; Reddy M.C.; Ti-O based nanomaterials ameliorate experimental autoimmune encephalomyelitis and collagen-induced arthritis. RSC Advances 2016,6(11),8870-8880","journal-title":"RSC Advances"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jaut.2013.02.005","volume":"43","author":"Robinson A.P.","year":"2013","unstructured":"Robinson A.P.; Caldis M.W.; Harp C.T.; Goings G.E.; Miller S.D.; High-mobility group box 1 protein (HMGB1) neutralization amelio-rates experimental autoimmune encephalomyelitis. J Autoimmun 2013,43,32-43","journal-title":"J Autoimmun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fimmu.2018.01518","volume":"9","author":"Sun Y.","year":"2018","unstructured":"Sun Y.; Chen H.; Dai J.; Wan Z.; Xiong P.; Xu Y.; Han Z.; Chai W.; Gong F.; Zheng F.; Glycyrrhizin protects mice against experi-mental autoimmune encephalomyelitis by inhibiting high-mobility group box 1 (HMGB1) expression and neuronal HMGB1 release. Front Immunol 2018,9,1518","journal-title":"Front Immunol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jneuroim.2015.02.005","volume":"280","author":"Sun Y.","year":"2015","unstructured":"Sun Y.; Chen H.; Dai J.; Zou H.; Gao M.; Wu H.; Ming B.; Lai L.; Xiao Y.; Xiong P.; Xu Y.; Gong F.; Zheng F.; HMGB1 expres-sion patterns during the progression of experimental autoimmune encephalomyelitis. J Neuroimmunol 2015,280,29-35","journal-title":"J Neuroimmunol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cei.13123","volume":"193","author":"Uzawa A.","year":"2018","unstructured":"Uzawa A.; Mori M.; Masuda H.; Ohtani R.; Uchida T.; Kuwabara S.; Recombinant thrombomodulin ameliorates experimental autoim-mune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clin Exp Immunol 2018,193(1),47-54","journal-title":"Clin Exp Immunol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/cei.12036","volume":"172","author":"Uzawa A.","year":"2013","unstructured":"Uzawa A.; Mori M.; Taniguchi J.; Masuda S.; Muto M.; Kuwabara S.; Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol 2013,172(1),37-43","journal-title":"Clin Exp Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"78","DOI":"10.15252\/emmm.201404392","volume":"7","author":"Ito H.","year":"2015","unstructured":"Ito H.; Fujita K.; Tagawa K.; Chen X.; Homma H.; Sasabe T.; Shimizu J.; Shimizu S.; Tamura T.; Muramatsu S.; Okazawa H.; HMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock-in mice. EMBO Mol Med 2015,7(1),78-101","journal-title":"EMBO Mol Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e115809","DOI":"10.1371\/journal.pone.0115809","volume":"9","author":"Lee L.C.","year":"2014","unstructured":"Lee L.C.; Chen C.M.; Wang P.R.; Su M.T.; Lee-Chen G.J.; Chang C.Y.; Role of high mobility group box 1 (HMGB1) in SCA17 patho-genesis. PLoS One 2014,9(12),e115809","journal-title":"PLoS One"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"863036","DOI":"10.1155\/2013\/863036","volume":"2013","author":"Abu El-Asrar A.M.","year":"2013","unstructured":"Abu El-Asrar A.M.; Nawaz M.I.; Siddiquei M.M.; Al-Kharashi A.S.; Kangave D.; Mohammad G.; High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina. Mediators Inflamm 2013,2013,863036","journal-title":"Mediators Inflamm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1159\/000343331","volume":"30","author":"Busch S.","year":"2012","unstructured":"Busch S.; Wu L.; Feng Y.; Gretz N.; Hoffmann S.; Hammes H.P.; Alzheimer\u2019s disease and retinal neurodegeneration share a consistent stress response of the neurovascular unit. Cell Physiol Biochem 2012,30(6),1436-1443","journal-title":"Cell Physiol Biochem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/labinvest.2015.156","volume":"96","author":"B&#xF6;hm M.R.","year":"2016","unstructured":"B&#xF6;hm M.R.; Schallenberg M.; Brockhaus K.; Melkonyan H.; Thanos S.; The pro-inflammatory role of high-mobility group box 1 pro-tein (HMGB-1) in photoreceptors and retinal explants exposed to elevated pressure. Lab Invest 2016,96(4),409-427","journal-title":"Lab Invest"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1167\/iovs.61.5.50","volume":"61","author":"Ross B.X.","year":"2020","unstructured":"Ross B.X.; Choi J.; Yao J.; Hager H.M.; Abcouwer S.F.; Zacks D.N.; Loss of high-mobility group box 1 (HMGB1) protein in rods ac-celerates rod photoreceptor degeneration after retinal detachment. Invest Ophthalmol Vis Sci 2020,61(5),50","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"S1347-8613(17), 30162-30167","DOI":"10.1016\/j.jphs.2017.09.031","author":"Sakamoto K.","year":"2017","unstructured":"Sakamoto K.; Okuwaki T.; Ushikubo H.; Mori A.; Nakahara T.; Ishii K.; Activation inhibitors of nuclear factor kappa B protect neurons against the NMDA-induced damage in the rat retina. J Pharmacol Sci 2017,S1347-8613(17), 30162-30167","journal-title":"J Pharmacol Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jneuroim.2017.11.003","volume":"313","author":"Das S.","year":"2017","unstructured":"Das S.; Mishra K.P.; Ganju L.; Singh S.B.; Andrographolide - A promising therapeutic agent, negatively regulates glial cell derived neu-rodegeneration of prefrontal cortex, hippocampus and working memory impairment. J Neuroimmunol 2017,313,161-175","journal-title":"J Neuroimmunol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.bbi.2019.09.003","volume":"82","author":"Das S.","year":"2019","unstructured":"Das S.; Mishra K.P.; Chanda S.; Ganju L.; Singh S.B.; CXCR7: A key neuroprotective molecule against alarmin HMGB1 mediated CNS pathophysiology and subsequent memory impairment. Brain Behav Immun 2019,82,319-337","journal-title":"Brain Behav Immun"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.neuropharm.2018.05.002","volume":"137","author":"Das S.","year":"2018","unstructured":"Das S.; Mishra K.P.; Ganju L.; Singh S.B.; Intranasally delivered small interfering RNA-mediated suppression of scavenger receptor Mac-1 attenuates microglial phenotype switching and working memory impairment following hypoxia. Neuropharmacology 2018,137,240-255","journal-title":"Neuropharmacology"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1074\/jbc.M117.786756","volume":"293","author":"Gasparotto J.","year":"2018","unstructured":"Gasparotto J.; Girardi C.S.; Somensi N.; Ribeiro C.T.; Moreira J.C.F.; Michels M.; Sonai B.; Rocha M.; Steckert A.V.; Barichello T.; Quevedo J.; Dal-Pizzol F.; Gelain D.P.; Receptor for advanced glycation end products mediates sepsis-triggered amyloid-&#x3B2; accumulation, Tau phosphorylation, and cognitive impairment. J Biol Chem 2018,293(1),226-244","journal-title":"J Biol Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/acn3.54","volume":"1","author":"Chang C.F.","year":"2014","unstructured":"Chang C.F.; Cho S.; Wang J.; (-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways. Ann Clin Transl Neurol 2014,1(4),258-271","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1471-4159.2007.04788.x","volume":"103","author":"Faraco G.","year":"2007","unstructured":"Faraco G.; Fossati S.; Bianchi M.E.; Patrone M.; Pedrazzi M.; Sparatore B.; Moroni F.; Chiarugi A.; High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem 2007,103(2),590-603","journal-title":"J Neurochem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"e0142901","DOI":"10.1371\/journal.pone.0142901","volume":"10","author":"Qi L.","year":"2015","unstructured":"Qi L.; Sun X.; Li F.E.; Zhu B.S.; Braun F.K.; Liu Z.Q.; Tang J.L.; Wu C.; Xu F.; Wang H.H.; Velasquez L.A.; Zhao K.; Lei F.R.; Zhang J.G.; Shen Y.T.; Zou J.X.; Meng H.M.; An G.L.; Yang L.; Zhang X.D.; HMGB1 promotes mitochondrial dysfunction-triggered striatal neurodegeneration via autophagy and apoptosis activation. PLoS One 2015,10(11),e0142901","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/jpet.117.245290","volume":"365","author":"Tajuddin N.","year":"2018","unstructured":"Tajuddin N.; Kim H.Y.; Collins M.A.; PARP Inhibition Prevents Ethanol-Induced Neuroinflammatory Signaling and Neurodegeneration in Rat Adult-Age Brain Slice Cultures. J Pharmacol Exp Ther 2018,365(1),117-126","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12974-017-0799-4","volume":"14","author":"Coleman L.G.","year":"2017","unstructured":"Coleman L.G.; Zou J.; Crews F.T.; Microglial-derived miRNA let-7 and HMGB1 contribute to ethanol-induced neurotoxicity via TLR7. J Neuroinflammation 2017,14(1),22","journal-title":"J Neuroinflammation"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1742-2094-9-130","volume":"9","author":"Qin L.","year":"2012","unstructured":"Qin L.; Crews F.T.; Chronic ethanol increases systemic TLR3 agonist-induced neuroinflammation and neurodegeneration. J Neuroinflammation 2012,9,130","journal-title":"J Neuroinflammation"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fnagi.2019.00369","volume":"11","author":"Bhatti G.K.","year":"2020","unstructured":"Bhatti G.K.; Reddy A.P.; Reddy P.H.; Bhatti J.S.; Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer\u2019s Disease. Front Aging Neurosci 2020,11,369","journal-title":"Front Aging Neurosci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnana.2015.00032","volume":"9","author":"Herrero M-T.","year":"2015","unstructured":"Herrero M-T.; Estrada C.; Maatouk L.; Vyas S.; Inflammation in Parkinson\u2019s disease: role of glucocorticoids. Front Neuroanat 2015,9,32","journal-title":"Front Neuroanat"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.tins.2008.07.004","volume":"31","author":"Williams A.J.","year":"2008","unstructured":"Williams A.J.; Paulson H.L.; Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 2008,31(10),521-528","journal-title":"Trends Neurosci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/14734220510007950","volume":"4","author":"Koeppen A.H.","year":"2005","unstructured":"Koeppen A.H.; The pathogenesis of spinocerebellar ataxia. Cerebellum 2005,4(1),62-73","journal-title":"Cerebellum"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3389\/fimmu.2019.01975","volume":"10","author":"Rashid K.","year":"2019","unstructured":"Rashid K.; Akhtar-Schaefer I.; Langmann T.; Microglia in retinal degeneration. Front Immunol 2019,10,1975","journal-title":"Front Immunol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"Frisoni G.B.","year":"2017","unstructured":"Frisoni G.B.; Boccardi M.; Barkhof F.; Blennow K.; Cappa S.; Chiotis K.; D&#xE9;monet J.F.; Garibotto V.; Giannakopoulos P.; Gietl A.; Hansson O.; Herholz K.; Jack C.R.; Nobili F.; Nordberg A.; Snyder H.M.; Ten Kate M.; Varrone A.; Albanese E.; Becker S.; Bos-suyt P.; Carrillo M.C.; Cerami C.; Dubois B.; Gallo V.; Giacobini E.; Gold G.; Hurst S.; L&#xF6;nneborg A.; Lovblad K.O.; Mattsson N.; Molinuevo J.L.; Monsch A.U.; Mosimann U.; Padovani A.; Picco A.; Porteri C.; Ratib O.; Saint-Aubert L.; Scerri C.; Scheltens P.; Schott J.M.; Sonni I.; Teipel S.; Vineis P.; Visser P.J.; Yasui Y.; Winblad B.; Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol 2017,16(8),661-676","journal-title":"Lancet Neurol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1038\/nrn1435","volume":"10","author":"Lansbury P.T.","year":"2004","unstructured":"Lansbury P.T.; Back to the future: the \u2018old-fashioned\u2019 way to new medications for neurodegeneration. Nat Med 2004,10(Suppl.),S51-S57","journal-title":"Nat Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13195-020-00601-w","volume":"12","author":"Ehrenberg A.J.","year":"2020","unstructured":"Ehrenberg A.J.; Khatun A.; Coomans E.; Betts M.J.; Capraro F.; Thijssen E.H.; Senkevich K.; Bharucha T.; Jafarpour M.; Young P.N.E.; Jagust W.; Carter S.F.; Lashley T.; Grinberg L.T.; Pereira J.B.; Mattsson-Carlgren N.; Ashton N.J.; Hanrieder J.; Zetterberg H.; Sch&#xF6;ll M.; Paterson R.W.; Relevance of biomarkers across different neurodegenerative diseases. Alzheimers Res Ther 2020,12(1),56","journal-title":"Alzheimers Res Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.soncn.2012.03.004","volume":"28","author":"Smith J.J.","year":"2012","unstructured":"Smith J.J.; Dunn B.K.; Biomarkers as molecular targets of drug interventions. Semin Oncol Nurs 2012,28(2),109-115","journal-title":"Semin Oncol Nurs"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neubiorev.2015.12.006","volume":"62","author":"Ray R.","year":"2016","unstructured":"Ray R.; Juranek J.K.; Rai V.; RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyo-trophic lateral sclerosis. Neurosci Biobehav Rev 2016,62,48-55","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tox.2015.10.010","volume":"338","author":"Tian J.","year":"2015","unstructured":"Tian J.; Dai H.; Deng Y.; Zhang J.; Li Y.; Zhou J.; Zhao M.; Zhao M.; Zhang C.; Zhang Y.; Wang P.; Bing G.; Zhao L.; The effect of HMGB1 on sub-toxic chlorpyrifos exposure-induced neuroinflammation in amygdala of neonatal rats. Toxicology 2015,338,95-103","journal-title":"Toxicology"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.gene.2016.11.022","volume":"600","author":"Paban V.","year":"2017","unstructured":"Paban V.; Loriod B.; Villard C.; Buee L.; Blum D.; Pietropaolo S.; Cho Y.H.; Gory-Faure S.; Mansour E.; Gharbi A.; Alescio-Lautier B.; Omics analysis of mouse brain models of human diseases. Gene 2017,600,90-100","journal-title":"Gene"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1096\/fj.09-139634","volume":"24","author":"Fang F.","year":"2010","unstructured":"Fang F.; Lue L.F.; Yan S.; Xu H.; Luddy J.S.; Chen D.; Walker D.G.; Stern D.M.; Yan S.; Schmidt A.M.; Chen J.X.; Yan S.S.; RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning\/memory in a mouse model of Alzheimer\u2019s disease. FASEB J 2010,24(4),1043-1055","journal-title":"FASEB J"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","volume":"26","author":"Yu M.","year":"2006","unstructured":"Yu M.; Wang H.; Ding A.; Golenbock D.T.; Latz E.; Czura C.J.; Fenton M.J.; Tracey K.J.; Yang H.; HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006,26(2),174-179","journal-title":"Shock"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"Kawai T.","year":"2010","unstructured":"Kawai T.; Akira S.; The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010,11(5),373-384","journal-title":"Nat Immunol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fncel.2015.00407","volume":"9","author":"Brudvig J.J.","year":"2015","unstructured":"Brudvig J.J.; Weimer J.M.; X MARCKS the spot: myristoylated alanine-rich C kinase substrate in neuronal function and disease. Front Cell Neurosci 2015,9,407","journal-title":"Front Cell Neurosci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4161\/auto.26751","volume":"10","author":"Song J-X.","year":"2014","unstructured":"Song J-X.; Lu J-H.; Liu L-F.; Chen L-L.; Durairajan S.S.K.; Yue Z.; Zhang H.Q.; Li M.; HMGB1 is involved in autophagy inhibition caused by SNCA\/&#x3B1;-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy 2014,10(1),144-154","journal-title":"Autophagy"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fnins.2018.00628","volume":"12","author":"Paudel Y.N.","year":"2018","unstructured":"Paudel Y.N.; Shaikh M.F.; Chakraborti A.; Kumari Y.; Aledo-Serrano &#xC1;.; Aleksovska K.; Alvim M.K.M.; Othman I.; HMGB1: A Common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci 2018,12,628","journal-title":"Front Neurosci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.expneurol.2011.08.012","volume":"232","author":"Mazarati A.","year":"2011","unstructured":"Mazarati A.; Maroso M.; Iori V.; Vezzani A.; Carli M.; High-mobility group box-1 impairs memory in mice through both toll-like recep-tor 4 and receptor for advanced glycation end products. Exp Neurol 2011,232(2),143-148","journal-title":"Exp Neurol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.4103\/1673-5374.197130","volume":"11","author":"Bortolotto V.","year":"2016","unstructured":"Bortolotto V.; Grilli M.; Not only a bad guy: potential proneurogenic role of the RAGE\/NF-&#x3BA;B axis in Alzheimer\u2019s disease brain. Neural Regen Res 2016,11(12),1924-1925","journal-title":"Neural Regen Res"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220114153308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200245\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X20666220114153308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T04:57:50Z","timestamp":1669093070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200245\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":126,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x20666220114153308","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}